Ticker Details
Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.
IPO Date:	February 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$563.2M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.74 | 3.80%
Avg Daily Range (30 D):	$0.16 | 5.32%
Avg Daily Range (90 D):	$0.13 | 4.62%

Institutional Daily Volume
Avg Daily Volume:	1.34M
Avg Daily Volume (30 D):	3.29M
Avg Daily Volume (90 D):	2.06M

Trade Size
Avg Trade Size (Sh.):	116
Avg Trade Size (Sh.) (30 D):	201
Avg Trade Size (Sh.) (90 D):	178

Institutional Trades
Total Institutional Trades:	3,837
Avg Institutional Trade:	$2.01M
Avg Institutional Trade (30 D):	$1.37M
Avg Institutional Trade (90 D):	$1.29M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.77M
Avg Closing Trade (30 D):	$1.52M
Avg Closing Trade (90 D):	$1.45M
Avg Closing Volume:	162.66K

News

Jul 3, 2026 @ 8:44 AM Gene Editing Therapeutics: Transforming Biopharmac... Source: Researchandmarkets.Com

Jul 3, 2026 @ 8:41 AM Global CRISPR-Based Drug Development Platforms Mar... Source: Researchandmarkets.Com

May 31, 2026 @ 4:11 PM CRISPR Therapeutics vs. Editas Medicine: Which Gen... Source: Robert Izquierdo

Apr 15, 2026 @ 6:00 PM Neutrolis Appoints Caren Deardorf as Chief Busines... Source: Not Specified

Mar 9, 2026 @ 11:00 AM Editas Medicine Announces Fourth Quarter and Full ... Source: Na

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.17	$-.26	$
Diluted EPS	$-1.17	$-.26	$
Revenue	$38.69M	$2.83M	$24.74M
Gross Profit
Net Income / Loss	$-108.95M	$-24.98M	$-5.62M
Operating Income / Loss	$-108.85M	$-25M	$-7.76M
Cost of Revenue
Net Cash Flow	$6.75M	$M	$-19M
PE Ratio